SweetBio Secures $900K Seed Round to Accelerate Breakthrough Collagen + Honey Wound Care Solutions

SweetBio, Inc. is excited to announce a significant milestone in its journey to revolutionize wound care: a successful funding raise of $900,000. As a commercial-ready, medical device company, SweetBio has made remarkable strides since the FDA clearance of its innovative, collagen plus honey advanced wound care products in May 2019. These novel products not only combine the regenerative benefits of collagen with the natural healing properties of honey but also embody the company’s mission to simplify your journey to closure—a promise that has resonated deeply with healthcare providers and patients alike. The fresh influx of capital will empower SweetBio to accelerate its mission by expanding its manufacturing capabilities, enhancing its research and development efforts, and extending the reach of its cutting-edge treatments to more healthcare facilities and patients in need. Strategic investments will be directed towards optimizing product formulations and scaling up operations to meet increasing market demand, ensuring that their wound care solutions remain at the forefront of medical innovation. Furthermore, this funding will support initiatives to drive broader market adoption and enhance educational outreach on the benefits of using natural, honey-incorporated wound care products. With its strong foundation and growing momentum under the hashtag #woundcareforall, SweetBio is well-positioned to lead the charge in transforming wound care solutions and improving patient outcomes. This pivotal funding announcement not only highlights investor confidence in SweetBio’s transformative approach but also marks an important step toward a future where advanced wound care is accessible and effective for everyone.